RETATRUTIDE

Retatrutide is a synthetic peptide engineered as a single-molecule agonist at three separate receptors — the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). AminoOptimization Group supplies it as a lyophilised research powder in 10 mg, 15 mg, 20 mg and 30 mg presentations, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.

What is Retatrutide?

Retatrutide is a synthetic peptide agonist engineered to act at three separate receptors: GLP-1R, GIPR, and GCGR. All three belong to the class B (secretin-like) family of G protein-coupled receptors and couple predominantly to Gs, activating adenylate cyclase on ligand binding. Published structure-activity work on the compound is concerned with how a single peptide backbone can be modified to retain functional activity at all three binding sites concurrently, rather than favouring one receptor with residual cross-reactivity at the others.

The backbone is built on the sequence of native GIP, with substitutions introduced at positions the literature identifies as determining cross-reactivity at GLP-1R and GCGR. A fatty diacid group is conjugated to a lysine side chain through a linker — a design element shared with other long-acting incretin-receptor peptides — and is reported to promote reversible, non-covalent binding to circulating albumin. This is the structural basis cited for the extended plasma half-life reported for this class of molecule relative to unmodified incretin peptides.

What distinguishes retatrutide within its structural family is the addition of glucagon receptor activity on top of the dual incretin-receptor engagement seen in earlier GIP/GLP-1 co-agonist designs. Published pharmacology papers describe this third receptor as a deliberate engineering target, and much of the in vitro characterization of the compound consists of comparative activation assays quantifying its potency at each receptor relative to the native hormones.

Specifications

• Compound: Retatrutide
• CAS number: 2381089-83-2
• Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular weight: 4731.33 g/mol
• Purity: 99% HPLC
• Presentation: Lyophilised powder, sealed vial
• Available sizes: 10 mg, 15 mg, 20 mg, 30 mg
• Physical form: White to off-white powder
• Classification: Research peptide — not for human or veterinary use

Research context

Published research on retatrutide is concentrated on receptor pharmacology. Comparative in vitro assays measure cyclic AMP accumulation in cell lines transfected with the human GLP-1, GIP, and glucagon receptors, characterizing the compound’s potency and selectivity ratio at each site relative to the endogenous hormones. This type of assay establishes whether a molecule engages all three targets rather than one dominant receptor with weak cross-reactivity at the other two.

A separate body of literature examines the pharmacokinetic consequence of the albumin-binding fatty acid conjugate, using animal models to characterize plasma clearance and circulating half-life relative to peptides lacking the modification. Receptor internalization and desensitization kinetics following sustained engagement have also appeared as study endpoints in cell-based systems, reflecting interest in how prolonged agonism at class B GPCRs differs from transient native-ligand signalling.

None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.

Reconstitution

Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.

Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.

Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.

Storage and stability

Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.

After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.

Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.

Certificate of Analysis

Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.

Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.

Handling and safety

Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.

Frequently asked questions

Is retatrutide approved in Canada?

No. Retatrutide has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no Drug Identification Number (DIN) and no Natural Product Number (NPN), its safety and efficacy in humans have not been established by any regulator, and it is supplied by AminoOptimization Group solely for laboratory research use — not for administration to humans or animals under any circumstance.

What distinguishes retatrutide from dual GIP/GLP-1 receptor agonists?

Structurally, the distinguishing feature is a third receptor target. Where dual agonists in this peptide family engage GIPR and GLP-1R, retatrutide’s backbone carries additional substitutions reported to confer activity at the glucagon receptor as well, making it a triple rather than dual agonist at the receptor level. Comparative potency data for each receptor are reported in the published pharmacology literature on the compound.

How much diluent should be used?

That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.

How long is reconstituted material usable?

Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.

Do you provide a Certificate of Analysis?

Yes — lot-specific, available on request, including before purchase.

Research use only

This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.